Princeton, New Jersey, United States, November 19, 2026
Bristol Myers Squibb (BMS) has announced an extensive programme of new clinical research across blood cancers and rare hematologic disorders ahead of the 68th American Society of Hematology (ASH) Annual Meeting and Exposition 2026. The company plans to present more than 90 company- and partner-sponsored scientific disclosures, including 24 oral presentations, at the meeting scheduled for December 12–15 in New Orleans, Louisiana. The research programme highlights developments across multiple myeloma, lymphoma, thalassemia and other hematologic conditions, with updates spanning investigational CELMoD medicines, next-generation CAR T-cell therapies and established treatments. Key clinical programmes include Phase 3 findings from the EXCALIBER-RRMM and SUCCESSOR-2 studies, Phase 2 data for golcadomide, and long-term follow-up from the pivotal TRANSFORM study evaluating Breyanzi (lisocabtagene maraleucel). The presentations reflect BMS’s continued investment in targeted protein degradation and cellular immunotherapies, with research exploring new treatment combinations and approaches for patients whose diseases have relapsed or become resistant to existing therapies.
CELMoD Programs Advance Multiple Myeloma and Lymphoma Research
A major focus of the ASH programme is the company’s cereblon E3 ligase modulator (CELMoD) portfolio, which includes iberdomide, mezigdomide and golcadomide. These investigational medicines are designed to influence protein degradation pathways and support anti-tumour activity. In multiple myeloma, BMS will present Phase 3 results from the EXCALIBER-RRMM study, evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone against a comparator regimen in patients with relapsed or refractory multiple myeloma. The oral presentation will include progression-free survival and minimal residual disease outcomes. Additional data from the Phase 3 SUCCESSOR-2 study will examine mezigdomide combined with carfilzomib and dexamethasone, including outcomes according to patients’ previous exposure to pomalidomide or T-cell-redirecting therapies. The programme also includes initial Phase 1 results evaluating mezigdomide with elranatamab, alongside research into its immune pharmacodynamic effects. In lymphoma, the company will present Phase 2 GOLSEEK-2 findings for golcadomide combined with rituximab in newly diagnosed advanced-stage follicular lymphoma. Other presentations will explore golcadomide combinations in newly diagnosed aggressive B-cell lymphoma and the investigational BCL6 degrader BMS-986458 in relapsed or refractory follicular lymphoma. These studies are intended to assess the potential of targeted protein degradation approaches across different blood cancer settings.
Next-Generation CAR T Therapies and Long-Term Breyanzi Data
BMS will also highlight progress in next-generation autologous CAR T-cell therapies for patients with relapsed or refractory multiple myeloma. One key presentation will report Phase 1 findings for tunlucabtagene autoleucel (BMS-986453), an investigational dual-targeting CAR T-cell therapy designed to recognise BCMA and GPRC5D. The programme will include safety and efficacy findings, while another Phase 1 presentation will examine arlocabtagene autoleucel, a GPRC5D-directed CAR T-cell candidate, including GPRC5D expression and genetic locus integrity. These approaches are being investigated to address treatment challenges in heavily pretreated multiple myeloma. In lymphoma, BMS will present five-year follow-up results from the Phase 3 TRANSFORM study, which evaluated Breyanzi against standard of care in second-line relapsed or refractory large B-cell lymphoma. The long-term analysis is expected to provide additional information on treatment outcomes and durability. The company will also share real-world effectiveness and safety comparisons between Breyanzi and bispecific antibodies in this patient population, together with a four-year update from the Phase 2 TRANSCEND FL study in patients with relapsed or refractory follicular lymphoma. Breyanzi is an approved CD19-directed autologous CAR T-cell therapy with multiple indications in certain blood cancers. Its use carries important risks, including cytokine release syndrome, neurological toxicities, serious infections and secondary malignancies, requiring appropriate monitoring and clinical management.
Research Expands into Rare Hematologic Disorders
Beyond blood cancers, the company’s ASH programme includes research involving luspatercept (Reblozyl) in thalassemia and other disorders associated with anemia. Phase 2 results will be presented for adults with non-transfusion-dependent alpha-thalassemia and hemoglobin H disease, while Phase 2a findings will examine luspatercept in adolescents with transfusion-dependent beta-thalassemia. Additional presentations will address anemia management in myelofibrosis and real-world outcomes in myelodysplastic syndromes. These studies demonstrate the breadth of BMS’s hematology research beyond oncology, including conditions that can require long-term management and supportive treatment. The upcoming congress presentations will provide researchers and clinicians with opportunities to review data across different disease areas, treatment mechanisms and stages of development. The findings should be interpreted according to each study’s design and clinical phase, particularly where investigational therapies are concerned. BMS’s announcement outlines the planned scientific disclosures rather than reporting all results in advance. The data presented at ASH 2026 may help inform future clinical development and treatment strategies, but investigational candidates will require further evaluation before any potential changes to clinical practice can be established.
Source: Bristol Myers Squibb press release



